| First Author | Yap JKY | Year | 2020 |
| Journal | J Immunol | Volume | 205 |
| Issue | 2 | Pages | 307-312 |
| PubMed ID | 32493814 | Mgi Jnum | J:291448 |
| Mgi Id | MGI:6445242 | Doi | 10.4049/jimmunol.2000513 |
| Citation | Yap JKY, et al. (2020) Inflammasomes and Pyroptosis as Therapeutic Targets for COVID-19. J Immunol 205(2):307-312 |
| abstractText | The inflammatory response to severe acute respiratory syndrome-related coronavirus 2 infection has a direct impact on the clinical outcomes of coronavirus disease 2019 patients. Of the many innate immune pathways that are engaged by severe acute respiratory syndrome-related coronavirus 2, we highlight the importance of the inflammasome pathway. We discuss available pharmaceutical agents that target a critical component of inflammasome activation, signaling leading to cellular pyroptosis, and the downstream cytokines as a promising target for the treatment of severe coronavirus disease 2019-associated diseases. |
